Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort

Armstrong, Matthew J.; Houlihan, Diarmaid D.; Bentham, Louise; Shaw, J; Cramb, Robert; Olliff, Simon; Gill, Paramjit; Neuberger, James; Lilford, Richard; Newsome, Philip N.

doi:10.1016/j.jhep.2011.03.020

Cited by 271 publications

(221 citation statements)

References 35 publications

Supporting

Mentioning

204

Contrasting

Unclassified

Order By: Relevance

“…Rather, the globalization of NAFLD runs parallel to the prevalence of obesity and varies accord ingly, with degree of hepatic triglyceride accumulation being directly proportional to the severity of each ele ment of the metabolic syndrome 25 Data from the Study of Health in Pomerania (SHIP) cohort in northeastern Germany estimates the preva lence of NAFLD to be ~30% when diagnosed by ultra sonography 26 . A UK based community study deter mined that NAFLD was the most common aetiology for asymptomatic abnormal liver biochemistry, accounting for 26.4% of cases (of whom 7.6% were predicted to have advanced liver disease) 27 . Similarly, a series of liver biop sies in individuals with unexplained abnormal liver tests conducted in France reported simple steatosis in 26.8% of patients, of whom 32.7% had NASH 28 .…”

Section: Nafld In Europementioning

confidence: 99%

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi

Anstee

Marietti³

et al. 2017

Nat Rev Gastroenterol Hepatol

4,154

3,198

View full text Add to dashboard Cite

Section: Nafld In Europementioning

confidence: 99%

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Younossi

Anstee

Marietti³

et al. 2017

Nat Rev Gastroenterol Hepatol

4,154

3,198

View full text Add to dashboard Cite

“…The Birmingham and Lambeth Liver Evaluation Testing Strategies [5,22] was a prospective cohort study of 1290 patients with abnormal LFTs in primary care who were subsequently fully characterised by clinical history, extensive blood testing and ultrasound of their abdomens. They were also followed up 2 years after the initial findings.…”

Section: Specificity and Sensitivity Of The Lftmentioning

confidence: 99%

Review and Recommendations for the Component Tests in the Liver Function Test Profile

Badrick

Turner

2015

Ind J Clin Biochem

View full text Add to dashboard Cite

Pathology laboratories group some tests that they perform on their high throughput biochemistry analysers into profiles of tests that are associated with different organs (e.g. liver function tests-LFT). The components of these profiles are historic and often vary between different laboratories. This can lead to confusion and begs the question of what should be in a particular profile. In community medicine profiles may be used as screening tests but some of the components of the profiles may have low sensitivity and specificity and may produce both false positives and negatives. The LFT may include components which are poor liver function tests but are sensitive to fatty liver and hence elevations may cause unnecessary concern. Harmonisation of clinical chemistry reference intervals and units is occurring now so it is time to consider a similar process for components of a profile. A proposed list of analytes to be performed in the LFT profile is given.

show abstract

“…Depending on the screening tool and when the study was performed, the estimated prevalence of NAFLD ranges from 2.8 to 46%. 2,3 Importantly up to 25% of NAFLD patients develop NASH, and in approximately one-third of NASH patients there is slowly progressive liver fibrosis leading to cirrhosis. 4,5 In 1998, the 'two hit' theory of disease pathogenesis was proposed in which lipid accumulation and steatosis as first hit sensitizes the liver to a variety of second hits (eg, oxidative stress) that lead to necroinflammation and fibrosis.…”

mentioning

confidence: 99%

Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis

Kampschulte

Stöckl

Langheinrich

et al. 2014

Laboratory Investigation

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease has been linked to cardiovascular diseases and atherosclerosis. The aim of the current study was to characterize the hepatic pathology leading to fibrosis and tumors in a murine model of atherosclerosis.Male apolipoprotein E/low-density lipoprotein receptor double-knockout mice (AL) mice were fed with a high fat and high cholesterol western diet for 35 weeks (AL mice on WD). Protein and mRNA analysis as well as micro-computed tomography (micro-CT) were performed to assess oxidative stress, liver damage, inflammation, fibrosis, signaling pathways, vascularization, and tumorigenesis. Controls were chosen to distinguish between genetically and dietary effects in steatohepatitis and associated tumorigenesis. Hepatic inflammation and dyslipidemia were increased in AL mice on WD compared with wild-type mice on WD. Uniquely, AL mice on WD showed a spontaneous development of tumors (30% of cases) and thickening of intrahepatic vessel walls. Functionally relevant underlying signaling pathways such as NF-kB, Stat3, JNK, and AKT were differentially regulated between AL and wild-type mice on WD. Micro-CT was capable of visualizing and quantitatively distinguishing tumor neovascularization from vascularization in non-neoplastic liver tissue. AL mice on WD diet represent a novel model combining atherosclerosis and nonalcoholic fatty liver disease. Signaling pathways of liver cell damage and compensatory liver regeneration in combination with enhanced inflammation appear to be crucial for the spontaneous development of tumors in AL mice on WD. Micro-CT represents a new and powerful technique for the ultrastructural and three-dimensional assessment of the vascular architecture of liver tumors.

show abstract

Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort

Abstract: NAFLD is the commonest cause of incidental LFT abnormalities in primary care (26.4%), of whom 7.6% have advanced fibrosis as calculated by the NFS. This study is the first of its kind to highlight the burden of NAFLD in primary care and provide data on disease severity in this setting.

Cited by 271 publications

References 35 publications

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Review and Recommendations for the Component Tests in the Liver Function Test Profile

Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis

Contact Info

Product

Resources

About